Certera Invests in Biosimulation
QSP is a combination of mathematical modeling and experimental methodologies that is used to better assess how drug compounds affect biological systems. QSP also aids in computing numerous clinical and preclinical experiments to indicate which experiments are likely to be most and least successful, thus improving efficiency and limiting R&D expenditures.
Princeton, NJ 12/1/15—Certara has purchased XenologiQ, a quantitative systems pharmacology (QSP) consultancy for an undisclosed amount. According to Certara, “QSP is an emerging biosimulation discipline that combines computational modeling and experimental methods to examine the mechanistic relationships between a drug, the biological system, and the disease process.” XenologiQ will become part of Certara’s Simcyp division, which provides mechanistic and physiologically based modeling platforms. “This transaction strengthens Certara’s modeling and simulation capabilities, increases its leadership in mechanistic pharmacology, and supports the company’s precision medicine vision,” stated Certara Chief Executive Officer Edmundo Muniz, MD, PhD. XenologiQ Director Piet van Graaf, PharmD, PhD, will join Certara as vice president, QSP, and Director Neil Benson, PhD, will join the company as head of QSP operations.
